评估影响孕期糖尿病母亲产后胰岛素抵抗标记的孕产妇因素 - - 一项病例对照研究
Karolina Karcz1, Paulina Gaweł1, Barbara Królak-Olejnik1
1Department of Neonatology, Wroclaw Medical University, 50-367 Wroclaw, Poland.
Nutrients
|November 27, 2024
概括
孕期糖尿病和怀孕体重增加影响产后胰岛素抵抗标志物. 甲状腺功能低下症也在这些变化中起作用,影响分娩后的母亲健康.
科学领域:
- 产科和妇科 产科和妇科
- 内分泌学 在内分泌学.
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 孕期糖尿病 (GDM) 在怀孕期间涉及复杂的胰岛素抵抗 (IR).
- 红外线病理生理学是多因素的,包括表观遗传学,环境,生活方式和心理社会因素.
研究的目的:
- 评估GDM和母亲因素对产后IR标志物的影响.
- 在产后第一周,比较GDM和正常葡萄糖耐受性母亲之间的IR标志物.
主要方法:
- 研究包括70名母亲:饮食/运动中的GDM,胰岛素中的GDM和非GDM对照.
- 分类学分析确定了预测因素:研究组,甲状腺功能低下史和妊娠期体重增加.
- 统计技术比较数据并确定了相关联.
主要成果:
- 确定了四个患者集群,其血糖查和三季度血糖水平各不相同.
- 在HOMA-IR或QUICKI产后没有显著差异.
- HbA1c结果显示,群体之间存在显著差异.
结论:
- 怀孕期间的葡萄糖代谢障碍,甲状腺功能低下和体重增加会影响分娩后的IR标志物.
- 孕期体重波动显著影响胎儿生长,出生体重和脂肪组织积累.
相关概念视频
Pathophysiology of Diabetes
868
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
868
Diabetes Mellitus: Type 2 and Gestational
2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
Oral Hypoglycemic Agents: Biguanides and Glitazones
174
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
174
Diabetes: Symptoms, Diagnosis, and Complications
506
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
506
Diabetes Mellitus: Overview and Type I Subtype
2.4K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.4K
Dipeptidyl Peptidase 4 Inhibitors
171
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
171


